Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 7, 2004, Pages 3469-3473

  Dupré, John ^a,b   Behme, Margaret T ^a   McDonald, Thomas J ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCOSE; PARACETAMOL;

ARTICLE; CONTROLLED STUDY; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; INGESTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PANCREAS; PRIORITY JOURNAL; REDUCTION; STOMACH EMPTYING;

ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTRIC EMPTYING; GLUCAGON; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; TIME FACTORS; VENOMS;

MAMMALIA; REPTILIA;

EID: 3242664057     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032001     Document Type: Article

References (23)

1. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B 1993 Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268:19650-19655
2. Holst JJ 2002 Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 18:430-441
3. Dupre J, Ross SA, Watson D, Brown JC 1973 Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826-828
4. Kreymann B, Williams G, Ghatei MA, Bloom SR 1987 Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300-1304
5. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide-1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307
6. Dupré J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ 1995 Glucagon-like peptide 1 reduces post-prandial glucose excursions in IDDM. Diabetes 44:626-630
7. Dupré J, Behme MT, Hramiak IM, McDonald TJ 1997 Sc glucagon-like peptide-1 combined with insulin normalizes postprandial glycemia in IDDM. Diabetes Care 20:381-384
8. Behme MT, McDonald TJ, Dupré J 2003 Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 3:3
9. Dupré J, Jenner M, Mahon JL, Purdon C, Rodger NW, Stiller CR 1991 Endocrine-metabolic function in remission-phase insulin-dependent diabetes mellitus (IDDM) during administration of cyclosporin. Diabetes 40:598-604
10. Pehling G, Tessari P, Gerich JE, Raymond MW, Service FJ, Rizza RA 1984 Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest 74:985-991
11. Dinneen S, Alzaid A, Turk D, Rizza R 1995 Failure of glucagon suppression contributes to postprandial hyperglycemia in IDDM. Diabetologia 38:337-343
12. Slezak LA, Andersen DK 2001 Pancreatic resection: effects on glucose metabolism. World J Surg 25:452-460
13. Kraegen EW, Chisholm DJ, McNamara ME 1981 Timing of insulin delivery with meals. Horm Metab Res 13:365-367
14. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322
15. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA 1996 Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
16. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, Elahi D 2003 Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care 26:837-842
17. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Gingerich R, Egan JM, Finegood DT, Elahi D 2001 Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes. Diabetes Care 24:1951-1961
18. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW 1994 Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93:2263-2266
19. The Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
20. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide-1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
21. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M 1999 Glucose-lowering and insulin-sensitizing actions of exendin-4. Studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic Rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034
22. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GW, Seal LJ, Ghatei MA, Bloom SR 2001 Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161
23. Batterham RL, LeRoux CW, Cohen MA, Park AJ, Ellis SM, Patterson M, Frost GS, Ghatei MA, Bloom SR 2003 Pancreatic polypeptide reduces appetite and food intake in humans. J Clin Endocrinol Metab 88:3989-3992